A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis - ICONIC-PsA 2

Start Date16 May 2025

Sponsor / Collaborator-

CTRI/2025/04/084370

/ RecruitingPhase 3

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-na ve Participants with Active Psoriatic Arthritis - ICONIC-PsA 1

Start Date08 May 2025

Sponsor / Collaborator-

NCT06934226

/ RecruitingPhase 3

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Start Date15 Apr 2025

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with Icotrokinra

100 Translational Medicine associated with Icotrokinra

100 Patents (Medical) associated with Icotrokinra

Literatures (Medical) associated with Icotrokinra

01 Mar 2025·JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

Article

Author: Ferris, Laura K ; Tyring, Stephen K ; Iaconangelo, Charles ; Ota, Takayuki ; Huang, Yu-Huei ; Shen, Yaung-Kaung ; Bissonnette, Robert ; Pink, Andrew E ; Bagel, Jerry ; Kokolakis, Georgios ; Li, Shu ; DeLozier, Amy M

BACKGROUND:

More patients with moderate-to-severe plaque psoriasis achieved responses with JNJ-77242113, a targeted oral peptide inhibiting interleukin-23 receptor signaling, versus placebo (PBO) at week (W)16 of the phase 2 FRONTIER-1 study.

OBJECTIVE:

FRONTIER-2, a long-term extension of FRONTIER-1, evaluated JNJ-77242113 through 1 year.

METHODS:

FRONTIER-1 participants received JNJ-77242113 at doses from 25 mg daily to 100 mg twice daily or PBO through W16. Patients completing FRONTIER-1 could enroll in FRONTIER-2 and continue JNJ-77242113 at the same dose through W52. Those on PBO crossed over to JNJ-77242113 100 mg daily for W16-52. Safety follow-up continued through W56.

RESULTS:

Most (89%) FRONTIER-1 patients continued to FRONTIER-2. Across outcomes, response rates were maintained from W16-52. The highest response rates generally occurred with JNJ-77242113 100 mg twice daily. At W52, 76% of patients achieved up to 75% improvement in Psoriasis Area and Severity Index (PASI75) with 100 mg twice daily; rates of clear or almost clear skin were 64% (PASI90), 74% (Investigator's Global Assessment 0/1), 40% (PASI100), and 43% (Investigator's Global Assessment 0). From W16-56, 59% of JNJ-77242113-treated patients had ≥1 adverse events. Serious adverse events, considered unrelated to treatment by investigators, occurred in 4% of patients.

LIMITATIONS:

The study was limited by the small number of patients in each treatment group and the descriptive nature of the longer-term data.

CONCLUSION:

Rates of skin clearance with JNJ-77242113 were durable to 1 year and no safety signals were identified.

01 Feb 2025·The Journal of clinical and aesthetic dermatology

From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.

Review

Author: Merola, Joseph F ; Gottlieb, Alice B ; Romanelli, Sarah ; Childs, Beth

Psoriasis (PsO) is an immune-mediated, chronic inflammatory skin disease that significantly impairs quality of life. Its treatment landscape is rapidly evolving, providing better disease control. Here, we highlight updates in biologics, obtaining coverage for biologics under Medicare, the PsO-to-psoriatic arthritis (PsA) transition, and orally administered drugs, as presented at the 2024 Masterclass in Dermatology in Puerto Rico. We provide a concise overview of the evolving therapeutic landscape and its impact on personalized care for patients with PsO. The toolkit of biologics is expanding, with agents that target interleukin (IL)-17 and IL-23 pathways addressing symptoms across multiple disease domains. Interchangeable biosimilars reduce financial barriers to access, particularly for tumor necrosis factor (TNF) inhibitors. An IL-36 receptor antibody, spesolimab, demonstrates efficacy in generalized pustular psoriasis. Further, Medicare has expanded coverage of certain biologics, addressing challenges to treating patients of this population. PsA is an important comorbidity that can significantly reduce quality of life. Recent studies suggest that biologic therapies-including TNF inhibitors, as well as anti-IL-17, anti-IL-23, and anti-IL-12/23 agents-protect against arthritis onset in PsO patients. In addition to traditional modes of delivery, novel formulations address widespread preference for orally administered therapies. Deucravacitinib, a tyrosine kinase (TYK) 2 inhibitor, is highly selective, effective, and safe. Additionally, JNJ-77242113, an investigational IL-23 receptor antagonist, constitutes an orally administered, targeted biologic therapy. Together, these developments are shaping the future for patients with PsO. It is our goal to simplify the complexities of emerging treatment options, offering clinicians a concise and useful guide for patient management.

08 Feb 2024·The New England journal of medicineQ1 · MEDICINE

An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis

Q1 · MEDICINE

Article

Author: Li, Shu ; Bissonnette, Robert ; Kannan, Arun ; Papp, Kim ; Shen, Yaung-Kaung ; Pinter, Andreas ; Ferris, Laura K. ; Miller, Megan ; Vender, Ronald ; Gerdes, Sascha ; Rich, Phoebe ; DeKlotz, Cynthia

BACKGROUND:

The use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection. JNJ-77242113 is a novel, orally administered interleukin-23-receptor antagonist peptide that selectively blocks interleukin-23 signaling and downstream cytokine production.

METHODS:

In this phase 2 dose-finding trial, we randomly assigned patients with moderate-to-severe plaque psoriasis to receive JNJ-77242113 at a dose of 25 mg once daily, 25 mg twice daily, 50 mg once daily, 100 mg once daily, or 100 mg twice daily or placebo for 16 weeks. The primary end point was a reduction from baseline of at least 75% in the Psoriasis Area and Severity Index (PASI) score (PASI 75 response; PASI scores range from 0 to 72, with higher scores indicating greater extent or severity of psoriasis) at week 16.

RESULTS:

A total of 255 patients underwent randomization. The mean PASI score at baseline was 19.1. The mean duration of psoriasis was 18.2 years, and 78% of the patients across all the trial groups had previously received systemic treatments. At week 16, the percentages of patients with a PASI 75 response were higher among those in the JNJ-77242113 groups (37%, 51%, 58%, 65%, and 79% in the 25-mg once-daily, 25-mg twice-daily, 50-mg once-daily, 100-mg once-daily, and 100-mg twice-daily groups, respectively) than among those in the placebo group (9%), a finding that showed a significant dose-response relationship (P<0.001). The most common adverse events included coronavirus disease 2019 (in 12% of the patients in the placebo group and in 11% of those across the JNJ-77242113 dose groups) and nasopharyngitis (in 5% and 7%, respectively). The percentages of patients who had at least one adverse event were similar in the combined JNJ-77242113 dose group (52%) and the placebo group (51%). There was no evidence of a dose-related increase in adverse events across the JNJ-77242113 dose groups.

CONCLUSIONS:

After 16 weeks of once- or twice-daily oral administration, treatment with the interleukin-23-receptor antagonist peptide JNJ-77242113 showed greater efficacy than placebo in patients with moderate-to-severe plaque psoriasis. (Funded by Janssen Research and Development; FRONTIER 1 ClinicalTrials.gov number, NCT05223868.).

140

News (Medical) associated with Icotrokinra

25 Jul 2025

·www.prnewswire.com

Weekly Recap: 12 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's $1.6B acquisition and a groundbreaking surgical nerve treatment for veterans. NEW YORK, July 25, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, July 21-25, 2025. Waystar to Acquire Iodine Software, Accelerating the AI-Powered Transformation of Healthcare Payments Waystar brings a decade-long track record of applying AI pervasively across its software platform to simplify healthcare payments. Iodine extends that leadership into clinical intelligence software, leveraging proprietary AI models trained on one of the industry's largest clinical datasets, representing more than a third of all U.S. inpatient discharges. Vicebio, next-generation vaccine biotech, to be acquired by Sanofi for US$1.6 billion "Vicebio and its incredibly passionate team have been driven by the ambition to develop next-generation vaccines aimed at targeting multiple life-threatening respiratory viruses simultaneously. This acquisition validates our ability to combine innovation and deep scientific expertise towards a common goal of advancing public health prevention," said Dr. Emmanuel Hanon, Chief Executive Officer of Vicebio. Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch Ategenos has been quietly developing a novel platform that integrates pharmaceutical science with real-time digital health technologies to address adherence in critical dose management. The company will share details on its SmartPatch platform and initial partnerships in the coming weeks. Cambridge Innovation Institute Announces Acquisition of Integrative Healthcare Symposium and Integrative Practitioner from Diversified "CII has been a leader in life science conferences for over three decades, and we are excited to add this new conference and publication covering other essential aspects of healthcare to our expanding CHI portfolio. The many facets of holistic medicine are growingly important within healthcare and will benefit from additional advancement via opportunities for knowledge sharing and collaboration," said Benjamin Lakin, PhD, CEO of Cambridge Innovation Institute. Answer ALS Launches AI Drug Development Collaboration with GATC Health, Pennington Biomedical Research Center, and Tulane to Advance ALS Treatment Discovery At the center of this effort is Dr. Jeffrey Keller of Pennington Biomedical, working in close partnership with Dr. Aron Culotta of Tulane. Together, they will lead a coordinated statewide effort of connecting researchers with expertise in AI, drug discovery, neuroscience, and clinical care, while all working together to drive innovation toward ALS treatments. Tulavi and VHSS Partner to Bring Groundbreaking Surgical Nerve Treatment to Veterans Impacted by Amputations and Traumatic Injuries The allay™ Hydrogel Cap is a novel, fully absorbable, and entirely sutureless medical device that provides a perfectly conforming and protective barrier to the injured nerve, supporting nerve recovery while reducing the risk of neuroma formation. Once deployed, the hydrogel cap remains in place for approximately eight months, protecting the nerve and blocking axonal escape during the critical period of neuroma formation. Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis "The rapid patient enrollment across our ICONIC clinical program underscores the unmet need for an advanced plaque psoriasis treatment that meaningfully addresses their needs and preferences," said Liza O'Dowd, MD, Vice President, Immunodermatology and Respiratory Disease Area Lead, Johnson & Johnson Innovative Medicine. New Non-Invasive Glaucoma Treatment Offered for First Time in U.S. Eyetronic therapy provides external neural stimulation to the optic nerve of patients suffering from glaucoma, a disease in which the optic nerve is permanently damaged resulting in vision loss. Glaucoma is the leading cause of irreversible blindness in the world, affecting over 4 million people in the U.S. and more than 80 million people worldwide . Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets "KLTO hopes to work with AAVnerGene for manufacturing several of our product candidates composed of a tissue-specific promoter driving our Klotho gene to produce the Klotho protein and elevated concentrations of the protein in specific, targeted tissues and organs affected by these neurologic and neuromuscular diseases," said Dr. Joseph Sinkule, the CEO of KLTO. Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management By leveraging Novo Nordisk's expertise and innovative products in diabetes and obesity treatment, Fangzhou plans to employ its smart healthcare ecosystem and robust technology infrastructure to create a comprehensive health management service. This will include medication guidance, reminders, efficacy tracking, and health education, effectively shaping the value chain in the glucose control and weight loss sector. Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping DMD is a rare genetic condition that is characterized by progressive muscle damage and weakness due to the loss of dystrophin protein that typically starts at a very young age. Del-zota is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study Results showed that a single dose administered by either intranasal (IN) or intramuscular (IM) routes induced neutralizing antibody responses (IN: 1:54; IM: 1:1,160), at or above the 1:40 titer generally considered to be a protective antibody response. The data showed even higher levels of immunity after two doses. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccineAcquisitionBreakthrough Therapy

22 Jul 2025

·firstwordpharma.com

Abivax flexes dual wins for obefazimod in pivotal ulcerative colitis studies

Abivax on Tuesday reported upbeat outcomes from two pivotal induction trials evaluating obefazimod, a first-in-class oral miR-124 enhancer, demonstrating significant remission rates in patients with moderate to severely active ulcerative colitis (UC). The news sent the company’s shares up nearly 500% in after-hours trading on Tuesday.“We are thrilled to report outcomes that not only met but exceeded the bar set by our Phase IIb trial,” said Fabio Cataldi, chief medical officer at Abivax. Earlier in the month, Citizens JMP analysts expressed confidence that the trials would read out positively, dubbing them as one of the “high-conviction clinical catalysts” of the third quarter.The Phase III ABTECT-1 and ABTECT-2 trials collectively enrolled 1,275 participants across 36 countries, who were randomised to receive one of two obefazimod doses once daily or placebo. Notably, 47.3% of participants previously had an inadequate response to advanced therapies, including JAK inhibitors.Top-line results from both trials showed that the 50-mg once-daily dose of obefazimod achieved the primary endpoint of clinical remission at week 8, with pooled remission rates of 16.4% versus placebo. Individual placebo-adjusted remission rates were 19.3% in ABTECT-1 and 13.4% in ABTECT-2. Moreover, the 50-mg dose met all key secondary endpoints, demonstrating significant benefits across clinical response, endoscopic improvement, and histologic-endoscopic mucosal improvement measures. On the other hand, the 25-mg dose of obefazimod met the main goal in ABTECT-1 with a 21.4% placebo-adjusted remission rate but failed to reach statistical significance in ABTECT-2. The lower dose, however, managed to achieve a a pooled clinical response rate of 28.6% versus placebo. Safety analysis revealed no new safety signals, with obefazimod showing favourable tolerability across both dose groups. Treatment-emergent adverse events resulting in discontinuation were reported in 5.3% and 4.7% of participants receiving the 50-mg dose in ABTECT-1 and ABTECT-2, respectively.Filings in worksMeanwhile, the ongoing ABTECT Maintenance trial has enrolled 678 patients who achieved clinical response from the induction trials, with top-line results expected in the second quarter of next year. “Pending successful results from the 44-week maintenance trial, we are preparing to submit a New Drug Application to the FDA in the second half of 2026,” said Abivax CEO Marc de Garidel. The ABTECT findings will likely prep Abivax for a potential showdown with Johnson & Johnson’s IL-23-blocking oral peptide icotrokinra (JNJ-2113), which hit the mark in a Phase IIb UC study earlier this year. For more on this, read: Vital Signs: Abivax swings for the fences to hit J&J.With Abivax quickly burning through its cash reserves — which stood at approximately $71.4 million as of June — the miR-124 enhancer could be a decisive asset for the French biotech.

Clinical ResultPhase 2Phase 3

22 Jul 2025

·www.biopharmadive.com

Replimune drug rejected by FDA; Omega raises $647M biotech fund

Today, a brief rundown of news involving Replimune Group and Johnson & Johnson, as well as updates from Omega Funds, iTeos Therapeutics and Roche that you may have missed.The Food and Drug Administration on Tuesday rejected a melanoma drug developed by Replimune. According to the Massachusetts-based biotechnology company, the agency said in a complete response letter that it did not consider the single-arm study Replimune ran to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. The FDA also cited differences among the patients enrolled and issues it had with Replimunes design of a confirmatory trial. In a statement, Replimune CEO Sushil Patelsaid the company was surprised by the FDAs decision, as the agency had not previously raised those issues in prior meetings. Analysts saw evidence of changing approval standards in the rejection: It is obvious [Replimune] got caught in a changing FDA regulatory landscape, Cantor Fitzgeralds Li Watsek wrote in a client note. Ned PagliaruloJohnson & Johnson on Monday asked the FDA to approve a new immune disease drug called icotrokinra that it and Protagonist Therapeutics developed for moderate-to-severe plaque psoriasis. The drug blocks a protein called IL-23 thats targeted by other available medicines, but, unlike those therapies, is delivered as a pill instead of an injection. J&Js application is backed by data from four trials that showed treatment could reliably clear skin. The company is also studying icotrokinrain ulcerative colitis and other immune diseases mediated by IL-23. Ned PagliaruloBiotech venture firm Omega Funds closed a $647 million fund, its eighth, to help fund investments in life sciences companies in the U.S. and Europe. Omega said Monday it exceeded its $600 million target, with strong support from both new and existing limited partners. Omega has raised more than $2.5 billion since its inception in 2004 and, since then, its portfolio companies have been involved in 47 initial public offerings and 50 acquisitions, among them the recent buyouts of Scorpion Therapeutics and Morphic Therapeutic, the firm said. Ben FidlerCancer drug developer iTeos Therapeutics will sell itself to Concentra Biosciences as part of a plan to wind down and disburse cash to its shareholders. The company, which revealed plans to liquidate in May, announced on Monday a deal through which Concentra will buy its assets for a little over $10 per share. Stockholders could receive additional consideration via a contingent value right if Concentra sells certain iTeos assets within six months or the companys cash holdings exceed $475 million at closing. The deal is the latest in a series of recent acquisitions for Concentra, a vehicle controlled by hedge fund Tang Capital Partners that buys struggling biotechs and shuts them down. Ben FidlerRoche is debating next steps for an experimental lung disease drug its been developing after reporting split results from two clinical studies of people with chronic obstructive pulmonary disease. While the drug, astegolimab, significantly reduced the annual attack rate in a Phase 2b trial, results from a similarly sized Phase 3 study didnt reach statistical significance, Roche said Monday. The observed reductions in annualized rate were about 15% in each study, but Roche noted that the total number of these exacerbations was lower than its scientists had expected when designing the trials. Roche Chief Medical Officer Levi Garraway said the company would discuss the data with health regulators. Ned Pagliarulo '

Clinical ResultAcquisitionPhase 2Drug ApprovalImmunotherapy

100 Deals associated with Icotrokinra

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	NDA/BLA	United States	Johnson & Johnson	21 Jul 2025
Arthritis, Psoriatic	Phase 3	United States	Janssen Research & Development LLC	09 Jan 2025
Arthritis, Psoriatic	Phase 3	China	Janssen Research & Development LLC	09 Jan 2025
Arthritis, Psoriatic	Phase 3	Japan	Janssen Research & Development LLC	09 Jan 2025
Arthritis, Psoriatic	Phase 3	Argentina	Janssen Research & Development LLC	09 Jan 2025
Arthritis, Psoriatic	Phase 3	Australia	Janssen Research & Development LLC	09 Jan 2025
Arthritis, Psoriatic	Phase 3	Brazil	Janssen Research & Development LLC	09 Jan 2025
Arthritis, Psoriatic	Phase 3	Bulgaria	Janssen Research & Development LLC	09 Jan 2025
Arthritis, Psoriatic	Phase 3	Canada	Janssen Research & Development LLC	09 Jan 2025
Arthritis, Psoriatic	Phase 3	Czechia	Janssen Research & Development LLC	09 Jan 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04621630 (Pubmed \| Dermatol Ther (Heidelb))	Phase 1	-	-	Icotrokinra	sxuoixymof(psqqlwvjrp) = snlrxdcnfu nvpjwcijki (ehlokjpokh ) View more	Positive	08 Jul 2025
				Placebo	sxuoixymof(psqqlwvjrp) = ncbggihfga nvpjwcijki (ehlokjpokh ) View more
NCT06095102 (ICONIC-TOTAL, PRNewswire) Manual	Phase 3	Plaque psoriasis	311	icotrokinra	kadmaqybfe(hptjcdyxia) = fkdshogasb jieyfazzqn (ydyvgmsvfl ) Met View more	Positive	09 May 2025
				placebo	kadmaqybfe(hptjcdyxia) = yxbkfcxloz jieyfazzqn (ydyvgmsvfl ) Met View more
NCT06095115 (ICONIC-LEAD, PipelineReview) Manual	Phase 3	Plaque psoriasis	-	Icotrokinra	mdqciwtbrz(asuksnlzrr) = uwstldvhlx dtqlkvvekt (cbtvkvktjr ) View more	Positive	10 Apr 2025
				Placebo	mdqciwtbrz(asuksnlzrr) = aeudixlnrr dtqlkvvekt (cbtvkvktjr ) View more
NCT06049017 (ANTHEM-UC, NEWS) Manual	Phase 2	Colitis, Ulcerative	252	Icotrokinra	zshklcdtoq(pbjlphcznj) = mbgcwpgugj sejxyanrcb (idgofxjgbx ) Met View more	Positive	10 Mar 2025
				Placebo	zshklcdtoq(pbjlphcznj) = zrexonburb sejxyanrcb (idgofxjgbx ) Met View more
NCT06095115 (ICONIC-LEAD, NEWS 1 \| NEWS 2) Manual	Phase 3	Plaque psoriasis	-	JNJ-77242113	xhjvxsqooy(nutfqdermj) = npkviulzvd jaqotpdllh (ldnirjdjma ) Met View more	Positive	18 Nov 2024
				Placebo	xhjvxsqooy(nutfqdermj) = adnuyivkil jaqotpdllh (ldnirjdjma ) Met View more
NCT06095102 (ICONIC-TOTAL, Company_Website) Manual	Phase 3	Plaque psoriasis	-	Icotrokinra	xwiqhbqfwo(smncmafrwg) = positive topline results from the Phase 3 ICONIC-TOTAL study showed once-daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo. wdmkmlcmlj (jlxlphxvym ) Met	Positive	18 Nov 2024
				Placebo
NCT05364554 (FRONTIER 2, PRNewswire) Manual	Phase 2	Plaque psoriasis	227	JNJ-2113	odsoqeewyv(mkdrziuzdd) = qkctcxowwi gbymnmwamh (ncdpfkwtun ) View more	Positive	09 Mar 2024
NCT05223868 (FRONTIER 1, Literature) Manual	Phase 2	Plaque psoriasis	255	JNJ-77242113 25 mg once daily	kscxudifrf(egvvzlrngr) = nnxnzxxoti rbdvshnxwc (qhaupobota ) Met	Positive	08 Feb 2024
				JNJ-77242113 25 mg twice daily	kscxudifrf(egvvzlrngr) = tsngqljktp rbdvshnxwc (qhaupobota ) Met
NCT05223868 (Pubmed \| N Engl J Med)	Phase 2	Plaque psoriasis	-	JNJ-77242113 25mg once daily	yxorcdoeeg(ylhphqpglj) = similar in the combined JNJ-77242113 dose group (52%) and the placebo group (51%) fmjwyxxxgd (whdemltnoy ) View more	-	08 Feb 2024
				JNJ-77242113 25mg twice daily
NCT05223868 (FRONTIER 1, WCD 12023 \| WCD 22023) Manual	Phase 2	Plaque psoriasis	255	JNJ-77242113 25 mg daily	jkhqobptks(ggilfmlqvd) = sbmobivnxj mncaxwbyof (ngptzcnhpm ) Met View more	Positive	04 Jul 2023
				JNJ-77242113 25 mg twice daily	jkhqobptks(ggilfmlqvd) = qatetsciot mncaxwbyof (ngptzcnhpm ) Met View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis